poisar

Stocks · News reference

Freedom Broker Raises Pfizer Price Target to $34

Freedom Broker has maintained its Buy rating on Pfizer and increased its price target to $34 from $33.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PFE
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. David Jagielski, Cpa

    Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028

    Pfizer plans to enter the GLP-1 market in 2028 with berobenatide, acquired through its Metsera purchase. Despite a late entry compared to competitors, Pfizer believes its strong commercial execution capabilities, operational scale, and expertise in rapid product rollout (demonstrated with COVID vaccine/pill) position it to become a market leader in the projected $190 billion GLP-1 market by 2035.

    PFELLYNVO
  3. Rj Fulton

    BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027

    BioNTech and Moderna are transitioning from pandemic-era COVID-19 vaccine dominance to sustainable businesses through oncology and other disease pipelines. BioNTech is favored for 2027 due to its stronger financial position (€16.2 billion cash, zero debt, positive cash flow) and expanding cancer treatment pipeline, while Moderna faces greater financial pressure from declining vaccine revenue despite promising late-stage cancer vaccine results.

    BNTXMRNABMYCELGRRHHBY
  4. Na

    HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute

    Halozyme Therapeutics raised its 2026 revenue guidance to $1.86-$1.925B driven by 44% growth in third-quarter royalties to $341M from established therapies and newer subcutaneous launches. The company is expanding its ENHANZE pipeline with new partner collaborations and preparing Hypercon for clinical testing, while facing a European patent dispute with Merck over KEYTRUDA Qlex.

    HALORHHBYBMYCELGRMRK
  5. Na

    NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs Decline

    Novavax reported Q3 2026 loss of 19 cents per share, beating estimates, with revenues of $68 million exceeding consensus. The company raised 2026 revenue guidance to $385-$415 million, primarily driven by a $125 million Sanofi milestone. Despite operational improvements and cost reductions, shares fell 8.2% as investors focused on the one-time nature of the milestone and dependence on a potential 2029 U.S. vaccine launch for profitability.

    NVAXSNYPFE